Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Uncontrolled Asthma Clear all
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

NCT01312961
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
50
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04719832
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
30
States / cities
Encinitas, California • Long Beach, California • Pasadena, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 23, 2026, 5:00 PM EDT
Active, not recruiting Phase 4 Interventional

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching Placebo, ICS/LABA
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Bakersfield, California • La Jolla, California • Lancaster, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173
View directory record Official record
Conditions
Asthma
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
17
States / cities
Tempe, Arizona • Newport Beach, California • Northridge, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

NCT01691521
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab IV, Mepolizumab SC, IV Placebo, SC Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Newport Beach, California • Riverside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Jul 23, 2026, 5:00 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

NCT07120503
View directory record Official record
Conditions
Asthma (Diagnosis)
Interventions
WIN378, Placebo
Drug
Lead sponsor
Windward Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Los Angeles, California • San Jose, California • Melbourne, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

NCT01673672
View directory record Official record
Conditions
Moderate to Severe Allergic Asthma
Interventions
CYT003, Placebo
Biological
Lead sponsor
Cytos Biotechnology AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

NCT02918019
View directory record Official record
Conditions
Asthma
Interventions
MSTT1041A, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

NCT01576718
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

NCT03706079
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
13 Years to 81 Years
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Dothan, Alabama • Gilbert, Arizona • Bakersfield, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

Tezepelumab Home Use Study

NCT03968978
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab (APFS), Tezepelumab (AI)
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Hoover, Alabama • Gilbert, Arizona • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test if TEV-48574 is Effective in Relieving Asthma

NCT04545385
View directory record Official record
Conditions
Asthma
Interventions
TEV-48574, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
55
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

NCT02869438
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718103
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
41
States / cities
Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

NCT06196879
View directory record Official record
Conditions
Severe Asthma
Interventions
Verekitug (UPB-101), Placebo
Drug
Lead sponsor
Upstream Bio Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
55
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

NCT04305405
View directory record Official record
Conditions
Severe Uncontrolled Asthma
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Orlando, Florida • Lincoln, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

NCT06020014
View directory record Official record
Conditions
Asthma
Interventions
AZD4604, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

NCT01000506
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 750, Mepolizumab 250, Mepolizumab 75, Placebo saline
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Riverside, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

NCT05763121
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
89
States / cities
Bakersfield, California • La Palma, California • Newport Beach, California + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

NCT06191315
View directory record Official record
Conditions
Wheezing, Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 5 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

NCT07276724
View directory record Official record
Conditions
Severe Asthma
Interventions
GB-0895, Placebo
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
12 Years to 80 Years
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Northridge, California • Pasadena, California • Rancho Cucamonga, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

NCT04410523
View directory record Official record
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Tralokinumab in Adults With Asthma

NCT01402986
View directory record Official record
Conditions
Asthma
Interventions
Placebo Q2W, Tralokinumab 300 mg, Q2W, Placebo, Q2/4W, Tralokinumab 300 mg, Q2/4W
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Rancho Mirage, California • Centennial, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 23, 2026, 5:00 PM EDT